All Articles

Traeger's revenue is down 17%, but its new Lowe's deal and aggressive cost-cutting signal a bold, risky pivot. Is this the right recipe for growth?

As York Space Systems names an interim CFO on the eve of its earnings report, the move signals a bid for stability in a volatile public market.

One Liberty Properties' stellar Q2 results aren't just good numbers; they're proof of a masterfully executed pivot to industrial real estate, a case study in navigating market shifts.

Beyond record revenues, Park-Ohio's Q2 results reveal a strategic pivot, leveraging AI, aerospace, and electrification to forge a less cyclical, high-growth future.

With soaring revenues and a landmark Microsoft AI deal, A10 Networks is redefining its role. Is this the playbook for winning the AI infrastructure wars?

Cytek Biosciences raises 2026 guidance on new tech, but rising costs and a wider net loss have investors questioning its path to sustainable profit.

The geospatial intelligence firm hit a key inflection point, converting 259% revenue growth into its first profitable quarter on an operating basis.

Despite trimming its 2026 guidance due to weather woes, Clearway Energy unveils a massive project pipeline, betting on long-term strategy over short-term stumbles.

The manufactured home builder is crushing estimates not by chasing trends, but by supplying the critical infrastructure for America's data center boom.

Revenues are up, but profits are down. BBSI's latest quarter reveals the hidden costs of a cooling labor market and rising insurance pressures.

As its acquisition looms, LiveRamp posts impressive growth and pivots hard into AI, signaling a new era for data collaboration under Publicis Groupe.

Chime posts a second GAAP profitable quarter, fueled by its premium tier and lending growth, but a surprise CFO exit raises questions about its next chapter.

Magnite's Q2 results show its CTV strategy is a powerful growth engine. The company beat estimates and raised its 2026 outlook, citing programmatic shifts.

The hormone optimization leader's stock tumbles after Q2 results show a net loss and declining revenue, revealing the prolonged impact of its January recall.

With a new $345 genome and major clinical wins, PacBio pushes boundaries. But can its strategic restructuring and bold R&D overcome mounting financial losses?

The clean-living brand's revenue is down, but profits and confidence are soaring. A deep dive into how strategic cuts are building a more durable company.

Gloo's acquisition of Cedarstone isn't just a merger. It's a strategic pivot to sell results, not software, aiming to unburden nonprofits with AI-powered services.

The agentic customer platform posts 20% revenue growth and a return to profitability, yet a softer forecast reveals underlying market pressures.

A new $105M SPAC enters the fray. We examine its veteran leadership, its cross-sector strategy, and what it takes to win in today's SPAC market.

KORU Medical posts record profits, but the real story is its strategic overhaul. We dissect its oncology pivot and digital tech bet for long-term value.